Fig. 6From: Argon plasma surface modification promotes the therapeutic angiogenesis and tissue formation of tissue-engineered scaffolds in vivo by adipose-derived stem cellsImmune response of the scaffolds over the 12 weeks. a CD68 macrophage assessment of the scaffolds treated with platelet-rich plasma (PRP), plasma (PM) and adipose-derived stem cells (ADSCs) at 12 weeks (n = 6). b Quantification of macrophage infiltration at 6 and 12 weeks. Note that there was no significant difference between the CD68 staining among the scaffolds. c CD45 leucocyte assessment of the scaffolds treated with platelet-rich plasma (PRP), plasma (PM) and adipose-derived stem cells (ADSCs) at 12 weeks (n = 6). d Quantification of CD45 leucocyte infiltration at 6 and 12 weeks. Note that there was no significant difference between the CD45 staining among the scaffolds. PU unmodified scaffolds, PRP platelet-rich plasma-modified scaffolds, PM argon-modified scaffold, PRP+PM platelet-rich plasma and argon modification. Arrows illustrate positive CD45 and CD68 stained cellsBack to article page